TNFRSF8 and uveal melanoma: We found that elevated CD30 expression in PBMCs was associated with poor survival in patients with uveal melanoma and those with breast, lung or colon cancer, indicating that CD30 could be used as a biomarker and therapeutic target that may determine disease outcomes after checkpoint therapy (Fig. 6q).